Rain Therapeutics Inc. (RAIN) financial statements (2022 and earlier)

Company profile

Business Address 8000 JARVIS AVENUE
NEWARK, CA 94560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

Current Assets
Cash, cash equivalents, and short-term investments140,218
Cash and cash equivalents24,780
Short-term investments115,438
Prepaid expense923
Deposits current assets19
Other current assets205
Other undisclosed current assets4,781
Total current assets:146,146
Noncurrent Assets
Operating lease, right-of-use asset386
Property, plant and equipment165
Other noncurrent assets443
Total noncurrent assets:994
Current Liabilities
Accounts payable and accrued liabilities11,806
Accounts payable6,112
Accrued liabilities5,694
Other undisclosed current liabilities4,509
Total current liabilities:16,315
Noncurrent Liabilities
Long-term debt and lease obligation252
Operating lease, liability252
Liabilities, other than long-term debt69
Other liabilities69
Total noncurrent liabilities:321
Total liabilities:16,636
Stockholders' equity
Stockholders' equity attributable to parent130,504
Common stock27
Additional paid in capital220,530
Accumulated other comprehensive loss(89)
Accumulated deficit(89,964)
Total stockholders' equity:130,504

Income statement (P&L) ($ in thousands)

Operating expenses(51,512)
Operating loss:(51,512)
Nonoperating income120
Investment income, nonoperating119
Loss from continuing operations before income taxes:(51,392)
Income tax expense(2)
Net loss available to common stockholders, diluted:(51,394)

Comprehensive Income ($ in thousands)

Net loss:(51,394)
Comprehensive loss:(51,394)
Other undisclosed comprehensive loss, net of tax, attributable to parent(89)
Comprehensive loss, net of tax, attributable to parent:(51,483)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: